Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid Tumors
James C. Tarr, James M. Salovich, Martin Aichinger, KyuOk Jeon, Nagarathanam Veerasamy, John Sensintaffar, Heribert Arnhof, Matthias Samwer, Plamen P. Christov, Kwangho Kim, Tobias Wunberg, Norbert Schweifer, Francesca Trapani, Allison L. Arnold, Florian Martin, Bin Zhao, Nagaraju Miriyala, Danielle Sgubin, Stuart A. Fogarty, William Moore, Gordon M. Stott, Edward T. Olejniczak, Harald Engelhardt, Dorothea Rudolph, Taekyu Lee, Darryl B. McConnell, Stephen W. Fesik
Abstract
and docetaxel or topotecan, respectively, resulted in an enhanced tumor response. These findings support the premise that pro-apoptotic priming of tumor cells by other therapies in combination with Mcl-1 inhibition may significantly expand the subset of cancers in which Mcl-1 inhibitors may prove beneficial.